What is the current valuation of the India respiratory drugs market?

The market valuation was $2862.0 Million in 2024. Read More

What is the projected market size for the India respiratory drugs market by 2035?

The projected valuation for 2035 is $5604.0 Million. Read More

What is the expected CAGR for the India respiratory drugs market during the forecast period 2025 - 2035?

The expected CAGR is 6.3% during the forecast period. Read More

Which drug class had the highest valuation in the India respiratory drugs market in 2024?

Inhaled Corticosteroids (ICS) had the highest valuation, ranging from $800.0 Million to $1500.0 Million. Read More

Which disease type is projected to have the highest market valuation in 2035?

Chronic Obstructive Pulmonary Disease (COPD) is projected to have the highest valuation, ranging from $1144.8 Million to $2200.8 Million. Read More

What is the market valuation range for Combination Drugs in 2024?

The market valuation for Combination Drugs ranged from $600.0 Million to $1200.0 Million. Read More

How does the distribution channel of retail pharmacies compare to hospital pharmacies in 2024?

Retail pharmacies had a valuation range of $1430.0 Million to $2800.0 Million, while hospital pharmacies ranged from $1144.0 Million to $2200.0 Million. Read More

What is the expected growth trend for inhalation route of administration in the coming years?

The inhalation route of administration had a valuation range of $1437.0 Million to $2802.0 Million and is expected to grow during the forecast period. Read More

What is the market valuation for antihistamines in 2024?

The market valuation for antihistamines ranged from $200.0 Million to $400.0 Million in 2024. Read More

India Respiratory Drugs Market

Q: What are the key players in the India respiratory drugs market?

Key players include Pfizer, Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Novartis, Teva Pharmaceutical Industries, Merck & Co., Sanofi, and Roche. Read More

ID: MRFR/Pharma/43776-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

India Respiratory Drugs Market Research Report By Drug Class (Short-Acting Beta2-Agonists (SABA), Long-Acting Beta2-Agonists (LABA), Inhaled Corticosteroids (ICS), Anticholinergics, Antihistamines, Vasodilators, Combination Drugs, Others), By Disease Type (Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Pleural Effusion, Others), By Route of Administration (Inhalation, Enteral, Parenteral) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Growth & Industry Forecast 2025 To 2035

India Respiratory Drugs Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.3%

2024 Market Size$ 2,862 Million

2025 Market Size$ 3,042.31 Million

2035 Market Size$ 5,604 Million

Key Players

Pfizer

Boehringer Ingelheim

GlaxoSmithKline

AstraZeneca

Novartis

Teva Pharmaceutical Industries

Trends

Rising Incidence of Respiratory Diseases
Technological Advancements in Drug Delivery
Government Initiatives and Regulations

Opportunities

Increasing Air Pollution Levels
Government Support and Policy Framework
Aging Population and Rising Healthcare Needs

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Drug Class (USD Million)
  1. 4.1.1 Short-Acting Beta2-Agonists (SABA)
  2. 4.1.2 Long-Acting Beta2-Agonists (LABA)
  3. 4.1.3 Inhaled Corticosteroids (ICS)
  4. 4.1.4 Anticholinergics
  5. 4.1.5 Antihistamines
  6. 4.1.6 Vasodilators
  7. 4.1.7 Combination Drugs
  8. 4.1.8 Others
2. 4.2 Chemicals and Materials, BY Disease Type (USD Million)
  1. 4.2.1 Asthma
  2. 4.2.2 Chronic Bronchitis
  3. 4.2.3 Chronic Obstructive Pulmonary Disease (COPD)
  4. 4.2.4 Pleural Effusion
  5. 4.2.5 Others
3. 4.3 Chemicals and Materials, BY Route of Administration (USD Million)
  1. 4.3.1 Inhalation
  2. 4.3.2 Enteral
  3. 4.3.3 Parenteral
4. 4.4 Chemicals and Materials, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacies
  2. 4.4.2 Retail Pharmacies
  3. 4.4.3 Online Pharmacies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Boehringer Ingelheim (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 GlaxoSmithKline (GB)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AstraZeneca (GB)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Novartis (CH)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Teva Pharmaceutical Industries (IL)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sanofi (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Roche (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 INDIA MARKET ANALYSIS BY DRUG CLASS
3. 6.3 INDIA MARKET ANALYSIS BY DISEASE TYPE
4. 6.4 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
5. 6.5 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY DISEASE TYPE, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Million)
  2. 7.2.2 BY DISEASE TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

India Chemicals and Materials Market Segmentation

Chemicals and Materials By Drug Class (USD Million, 2025-2035)

Short-Acting Beta2-Agonists (SABA)
Long-Acting Beta2-Agonists (LABA)
Inhaled Corticosteroids (ICS)
Anticholinergics
Antihistamines
Vasodilators
Combination Drugs
Others

Chemicals and Materials By Disease Type (USD Million, 2025-2035)

Asthma
Chronic Bronchitis
Chronic Obstructive Pulmonary Disease (COPD)
Pleural Effusion
Others

Chemicals and Materials By Route of Administration (USD Million, 2025-2035)

Inhalation
Enteral
Parenteral

Chemicals and Materials By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”